You are here

Press Releases

June 2, 2015
Andrew Fish, executive director of AdvaMedDx, issued the following statement on today’s White House Forum on Antibiotic Stewardship: “AdvaMedDx commends the administration for convening today’s meeting of key stakeholders dedicated to reducing... Read More
May 5, 2015
Andrew Fish, executive director of AdvaMedDx, issued the following statement on today’s Senate HELP Committee hearing on “Realizing the Promise of Precision Medicine for Patients”: “We commend Chairman Lamar Alexander (R-Tenn.) and Ranking Member... Read More
January 30, 2015
Andrew Fish, executive director of AdvaMedDx, issued the following statement today in response to President Barack Obama’s newly announced Precision Medicine Initiative: “We appreciate the Administration’s support for increased investments in... Read More
January 21, 2015
Andrew Fish, executive director of AdvaMedDx, issued the following statement today in response to a proposal to develop a large-scale genomics project, as referenced in last night’s State of the Union address by President Barack Obama: “The field of... Read More
January 8, 2015
Andrew Fish, executive director of AdvaMedDx, issued the following statement today on FDA’s public workshop on a Framework for Regulatory Oversight of Laboratory Developed Tests (LDTs): “AdvaMedDx commends FDA for holding this meeting and gathering... Read More
November 12, 2014
By John L. Bishop Diagnostic tests are increasingly a cornerstone of the modern health care system, providing critical information at every stage of patient care. Advanced molecular diagnostics are at the heart of an ongoing revolution in early... Read More
September 30, 2014
Andrew Fish, executive director of AdvaMedDx, released the following statement regarding the release of draft guidance by FDA on the regulation of laboratory-developed tests (LDTs): “AdvaMedDx appreciates FDA’s release of draft guidance on a risk-... Read More
September 18, 2014
Andrew Fish, executive director of AdvaMedDx, a division of the Advanced Medical Technology Association (AdvaMed) focused on diagnostics policy matters, released the following statement in response to the Obama Administration’s actions to fight... Read More
September 9, 2014
Andrew Fish, executive director of AdvaMedDx, testified before the U.S. House of Representatives Energy and Commerce Committee today in support of FDA taking a risk-based approach to the regulation of lab-developed tests (LDTs), which have grown... Read More
July 31, 2014
WASHINGTON, D.C. – Andrew Fish, executive director of AdvaMedDx, released the following statement regarding FDA’s congressional notification and draft framework on the regulation of laboratory-developed tests (LDTs): “AdvaMedDx welcomes the... Read More

Pages